RxDoctor Payments Data

Parveen Shiraz, MD

Hematology · Stanford, CANPI 1982754784

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,000 of the $1,000 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, CSL Behring. That places this record below the midpoint for hematology clinicians in CA, where the typical reported total is $4,615.

$1,000in general payments, 2019–2025

Across 1 payment — averaging $1000.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$1K
$820,316in research payments, 2019–2025

Across 38 payments — averaging $21,587 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$529K
  • CSL Behring$183K
  • National Marrow Donor Program$109K

What the payments were for

  • Travel & lodging$1,000100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
CSL Behring1$1,000

How this compares

$1,000 in reported general payments places this provider in the 35th percentile of 178 hematology providers in California.

See all hematology providers in California

Medicare billing

Part B allowed, 2024
$21,609
Medicare patients
43
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezurockBelumosudil Mesylate39$715,238
JakafiRuxolitinib Phosphate24$218,991
SprycelDasatinib15$149,126
Atovaquone11$4,436
Budesonide DrBudesonide13$2,381
Sirolimus14$1,856
Acyclovir84$1,549
Dexamethasone12$921
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim59$472
Tacrolimus11$467
Potassium Chloride11$258
Gabapentin17$194
Pantoprazole Sodium11$179
Prednisone11$115
Amoxicillin13$49

Paid to pharmacies, not to this prescriber.

Other hematology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →